Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.
about
Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialityDetermination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networksCarbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancerNoninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging studyHyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.A novel angiogenesis inhibitor bevacizumab induces apoptosis in the rat endometriosis model.Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data.Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.Mechanisms of glioma-associated neovascularization.Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathwaysModeling efficacy of bevacizumab treatment for metastatic colon cancer.Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.Role of apoptosis in colon cancer biology, therapy, and preventionResidual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?Tumor cell response to bevacizumab single agent therapy in vitroEfficacy of suicide gene therapy in hypoxic rat 9L glioma cells.Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab.Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma.CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer.Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab.
P2860
Q27025007-B6A1EC61-DBDA-4846-85B8-4435C7AE6DB4Q30475052-7FA478E9-6217-4CCF-BFE0-B93A23BF167EQ33484460-49102171-9F29-4E77-A182-7DD46B7642BFQ33655366-CE55A214-2EDB-4341-BC1F-A905E6AA5D0BQ34120237-FFF98D6C-0CC0-416A-9117-E7D0E21A234EQ35475535-320BCD6D-6D8B-4234-A516-2B87944D55C1Q35549659-6B2483C0-7806-447A-A8EC-D31336B75CF1Q35835574-BCA39752-B0BF-418F-B7DB-03BC303B791DQ35966871-1836D892-BC0A-42A3-92B7-99052D6D8247Q36070321-FE62018B-8558-4C41-A3EA-FAA635FB37F4Q36105171-A61925BD-1B68-400F-AAE7-1026AE90C212Q36295477-DEFE2B8E-4489-41C1-AA21-18B1F9A3E1BCQ36545995-B18BD40B-11D8-4047-A840-EDCE2B33432CQ36845505-A67896C4-1AAA-44E6-8AF5-8710C625F6EEQ37316035-C384C67F-2F54-43D5-AE58-A3AC4A63DF09Q37331465-34054DCA-6419-4A21-A7FD-FEF9D384CA1CQ37450606-2FD2D2FD-148E-4569-BA7F-4DEC2FB1CAB3Q37592390-2899A6F9-5E6E-4E4F-9343-0FBBE6414DDAQ38152999-F916BEC5-66D3-418E-AD4D-1B18BEFEBF91Q38672966-4B8CE9BA-B6DB-4B7E-8DB0-7E3C49FFF19DQ39092845-53F063CB-7F7A-4B19-8617-1457BB747B42Q39966239-E848B4F9-4681-41CD-88EC-752E2759DF11Q40468319-8D194960-02D7-4897-B3F1-151FB7A34A86Q40611973-B3C43051-0847-45B9-A4C5-865938014BC9Q47192935-47676B64-CCD0-4F0E-83C9-5C9102DF2074Q48099359-81F1CD0A-39EA-42CC-9B62-15DBC42FE5F6Q55518414-8F0F8220-484E-4201-97A4-0D14756F575E
P2860
Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antitumor effect of the angiog ...... to hypoxia-induced apoptosis.
@en
Antitumor effect of the angiog ...... to hypoxia-induced apoptosis.
@nl
type
label
Antitumor effect of the angiog ...... to hypoxia-induced apoptosis.
@en
Antitumor effect of the angiog ...... to hypoxia-induced apoptosis.
@nl
prefLabel
Antitumor effect of the angiog ...... to hypoxia-induced apoptosis.
@en
Antitumor effect of the angiog ...... to hypoxia-induced apoptosis.
@nl
P2093
P2860
P921
P1476
Antitumor effect of the angiog ...... to hypoxia-induced apoptosis.
@en
P2093
Kang Shen Yao
Michael D Feldman
Muthu Selvakumaran
Peter J O'Dwyer
P2860
P304
P356
10.1016/J.BCP.2007.09.029
P407
P577
2007-10-11T00:00:00Z